Posted by Michael Wonder on 06 Sep 2024
Fedratinib dihydrochloride monohydrate for the treatment of patients with disease-related splenomegaly or symptoms in myelofibrosis
6 September 2024 - The Department of Health and Social Care has asked NICE to review its guidance on the use of fedratinib dihydrochloride monohydrate in the NHS in England.
For the time being, fedratinib dihydrochloride monohydrate is not recommended for the treatment of adults with disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis who have not had a Janus kinase inhibitor or have been treated with ruxolitinib phosphate.
